Sinopep-Allsino Bio Pharmaceutical Adjusts Valuation Amid Rising Costs and Market Underperformance

Sinopep-Allsino Bio Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The stock's valuation score has been revised, reflecting a shift in its perceived financial standing. Key financial metrics indicate a P/E ratio of 29, which positions the stock as relatively high compared to industry standards. The Price to Book Value stands at 2.86, while the EV to EBIT and EV to EBITDA ratios are recorded at 26.31 and 16.23, respectively. Additionally, the EV to Capital Employed is noted at 2.15, and the EV to Sales ratio is 5.62. Recent performance indicators show a ROCE of 8.17% and an ROE of 9.72%. However, the company has faced challenges, including a significant debt-equity ratio of 60.35% and a low interest coverage ratio of 879.16. Furthermore, raw material costs have increased by 6.78% year-over-year. Despite these factors, Sinopep-Allsino has underperformed the market, with a return of -16.38% over the past year, contrasting sharply with the China Shanghai Composite's return of 22.49%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.